6 Top Gainers In Healthcare Sector (TCDA, TENX, SNSS...)
(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.
1. Tricida Inc. (TCDA)
Gained 57.04% to close Thursday's (Mar.28) trading at $37.80.
News: The Company reported positive results from its 40-week safety extension trial, which evaluated TRC101 in chronic kidney disease patients with metabolic acidosis.
In the trial, dubbed TRCA-301E, patients treated with TRC101 showed a significant reduction in all-cause mortality and progression of chronic kidney disease versus placebo within just one year in a prespecified analysis. There was also a significant improvement from baseline in measures of physical function and physical function-related quality of life in patients treated with TRC101 compared to placebo.
-- Availability of NDA-enabling 12-month registration stability data for TRC101 in mid-2019. -- Submission of NDA for TRC101, seeking approval of TRC101 through the FDA's Accelerated Approval Program, in the second half of 2019.
2. Tenax Therapeutics Inc. (TENX)
Gained 24.31% to close Thursday's trading at $2.25.
News: No news
-- A phase II trial of Levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), dubbed H-E-L-P Trial, is underway.
3. Sunesis Pharmaceuticals Inc. (SNSS)
Gained 17.82% to close Thursday's trading at $1.19.
News: No news
Clinical Trials & Near-term Catalyst:
-- A phase 1b/2 trial of Vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies is ongoing. -- An update on the ongoing Vecabrutinib trial is expected to be provided at the European Hematology Association Congress (EHA) in June 2019.
4. MYOS RENS Technology Inc. (MYOS)
MYOS is a nutrition company and the owner of Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle.
Gained 14.89% to close Thursday's trading at $1.62.
News: The Company reported financial results for the fourth quarter and fiscal year ended December 31, 2018.
Net loss for the fourth quarter of 2018 narrowed to $62 thousand from $1.01 million in the year-ago quarter. Net sales for the recent fourth quarter were $149 thousand, a decrease of 5%, compared to $157 thousand for the quarter ended December 31, 2017.
The Company expects to deliver increased sales in 2019 for its Fortetropin-based product brands.
5. Adial Pharmaceuticals Inc. (ADIL)
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder.
Gained 10.20% to close Thursday's trading at $3.24.
News: No news
Pipeline & Near-term Catalyst:
-- The Company's lead product candidate is AD04, a genetically targeted therapeutic agent, for the treatment of alcohol use disorder, and opioid use disorder.
In a phase IIb trial, AD04 showed promising results in reducing the frequency of drinking, quantity of drinking and heavy drinking in patients with alcohol use disorder.
-- Adial plans to commence the initial phase III trial of AD04 in Scandinavia and Eastern Europe during the first half of 2019.
6. Natera Inc. (NTRA)
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA.
Gained 9.74% to close Thursday's trading at $19.95.
News: No news
-- On March 13, the Company reported financial results for the fourth quarter and year ended December 31, 2018.
Net loss for the fourth quarter of 2018 narrowed to $31.8 million or $0.51 per share from $47.2 million or $0.90 per share for the same period in 2017. Total revenues for the recent fourth quarter increased 29% to $67.0 million from $52.0 million for the fourth quarter of 2017.
Total revenues for full-year 2018 were $257.7 million compared to $209.6 million for 2017, which represents an increase of 23%.
Looking ahead, the Company anticipates 2019 total revenues of $275 million to $302 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.